An Economic Evaluation of Triage Tools For Patients With Suspected Severe Injuries In England

Daniel Pollard (d.j.pollard@sheffield.ac.uk)
University of Sheffield

Gordon Fuller
University of Sheffield

Steve Goodacre
University of Sheffield

Eveline A. J. van Rein
University Medical Center Utrecht

Job, F. Waalwijk
University Medical Center Utrecht

Mark van Heijl
University Medical Center Utrecht

Research Article

Keywords: Major Trauma, Severe Injuries, Triage Tools, Economic Evaluation

DOI: https://doi.org/10.21203/rs.3.rs-504608/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Many health care systems triage injured patients to major trauma centres (MTCs) or local hospitals by using triage tools and paramedic judgement. Triage tools are typically assessed by whether patients with an Injury Severity Score (ISS) ≥ 16 go to an MTC and whether patients with an ISS = 16 are sent to their local hospital. There is a trade-off between sensitivity and specificity of triage tools, with the optimal balance being unknown. We conducted an economic evaluation of major trauma triage tools to identify which tool would be considered cost-effective by UK decision makers.

Methods

A patient-level, probabilistic, mathematical model of a UK major trauma system was developed. Patients with an ISS ≥ 16 who were only treated at local hospitals had worse outcomes compared to being treated in an MTC. Nine empirically derived triage tools, from a previous study, were examined so we assessed triage tools with realistic trade-offs between triage tool sensitivity and specificity. Lifetime costs, lifetime quality adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs) were calculated for each tool and compared to maximum acceptable ICERs (MAICERs) in England.

Results

Four tools had ICERs within the normal range of MAICERs used by English decision makers (£20,000 to £30,000 per QALY gained). A low sensitivity (28.4%) and high specificity (88.6%) would be cost-effective at the lower end of this range while higher sensitivity (87.5%) and lower specificity (62.8%) was cost-effective towards the upper end of this range. These results were sensitive to the cost of MTC admissions and whether MTCs had a benefit for patients with an ISS between 9 and 15.

Conclusions

The cost-effective triage tool depends on the English decision maker's MAICER for this health problem. In the usual range of MAICERs, cost-effective prehospital trauma triage involves clinically suboptimal sensitivity, with a proportion of seriously injured patients (at least 10%) being initially transported to local hospitals. High sensitivity trauma triage requires development of more accurate decision rules; research to establish if patients with an ISS between 9 and 15 benefit from MTCs; or, inefficient use of health care resources to manage patients with less serious injuries at MTCs.

Background

Major trauma is a significant problem worldwide, with a World Health Organisation report identifying that injuries were responsible for 9% of all deaths in 2012.[1] Systems and interventions to improve the outcomes of patients with injuries represent a key area in which public health can be improved worldwide.

Major trauma centres (MTCs), which concentrate severely injured patients in specialist centres, were introduced in England in 2012. Similar systems have been in use in some regions of the USA for many decades. In MTC systems if patients are suspected to be severely injured then paramedics will bypass local hospitals, if these are closer than the MTC, and the MTC will be pre-alerted to allow activation of a specialist major trauma team for resuscitation and initial management. Evidence from the USA shows that patients who have an injury severity score (ISS) of 16 or more would, on average, have better outcomes if they were treated at a major trauma centre.[2–6] Consequently, severe injuries are often defined in the literature as patients whose ISS was 16 or more. However, ISS can only be derived after the patient has been diagnosed and treated, therefore it is not always clear which hospital the paramedics should decide to transport the patients to. Furthermore, there is a definition of severe injuries that defines severe injuries as those injuries that would benefit from care that is only available at MTCs in a US setting.[7] As this is not yet widely used in the literature, we use the ISS is greater than or equal to 16 definition throughout.

van Rein et al. conducted a systematic review of studies assessing the effectiveness of triage tools in MTC systems.[8] This study found that no study which had a high methodological quality produced a tool that had adequate performance. Consequently, there is clinical value in developing, testing and implementing triage tools for patients with suspected major trauma that can be applied by paramedics when initially assessing an injured patient. Existing triage tools consist of physiological, anatomical, injury characteristic, and injury mechanism variables. Sensitivity and specificity are dependent on which variables are included in the triage tool and the cut-off level chosen for constituent variables, to give a positive diagnosis of major trauma. Any triage tool, will trade-off the number of true positive cases correctly admitted to major trauma centres (sensitivity), with the number of true negative cases correctly transported to local hospitals (specificity). However, it is uncertain where the optimal balance of sensitivity and specificity lies as the use of MTCs is associated with improved outcomes for severely injured patients, but also costs more.

The aim of this paper is to conduct a cost-utility analysis of several plausible major trauma triage tools from the perspective of a UK decision maker. Secondary outcomes of the decision analytic model include system flows of patients throughout the model, as this will influence which tools are feasible.

Methods

Modelling approach

We developed a lifetime patient-level decision tree, followed by a discrete event simulation to model patient flows through an English MTC system. The model estimated patient's outcomes, costs incurred and quality adjusted life years (QALYs) accrued for patients with suspected severe injuries. Conceptual modelling, informed by a previously published model by Newgard et al and consultation with subject experts informed the final model design.[9] We have taken a patient-level approach for two reasons. Firstly, we can accurately predict the risk of death using a validated 30-day probability of survival equation,
developed by the Trauma Audit and Research Network (TARN), in an English population.\[10, 11\] Secondly, when actual tools are assessed in English populations, this model can be easily adapted to include any correlations that exist between triage tool outcomes and the patient's probability of survival predicted by the TARN survival equation.

**Patient Population**

Our model considered patients who were injured outside of the MTC's local area for two reasons. Firstly, patients who live closest to an MTC will usually go to the MTC regardless of the severity of their injury. However, if a patient is thought to be severely injured, the MTC will be pre-alerted. Secondly, the available effectiveness evidence appears to treat all patients who live closest to an MTC as having been treated at an MTC regardless of whether the trauma team were pre-alerted. Consequently, there is no trade-off between cost and effectiveness that can be assessed in our analyses.

The model was populated with simulated patients' representative of injured patients presenting to an English trauma system. To generate these characteristics we obtained access to baseline demographic and clinical data from a recent prehospital major trauma triage study by van Rein et al, using the data collected in the Central Netherlands region.\[12\] This provided a high quality data set, which should be representative of developed world patient. This data is summarised in Table 1. Means, standard deviations and covariances between all parameters were obtained from the van Rein et al data for patients with complete data for Age, Gender, ISS, Glasgow Coma Scale (GCS) and trauma type.\[12\] Simulated patients were sampled using correlated draws from these distributions, further details are provided in the appendix.

**Table 1: A summary of the simulated characteristics of the patients included in the model**

| Characteristic          | Mean | SD / n/N | Source                                                                 |
|-------------------------|------|----------|------------------------------------------------------------------------|
| Age                     | 46.8 | 21.3     | Patients with complete Age, Gender, ISS, GCS and trauma type data in Van Rein et al\[12\] |
| Percentage Male         | 58.3%| 2887/4720|                                                                        |
| ISS                     | 5.2  | 7.2      |                                                                        |
| Percentage with an ISS \(\geq 16\) | 9.1% | 428/4720 |                                                                        |
| GCS                     | 14.4 | 1.9      |                                                                        |
| Percentage with blunt trauma | 98.2%| 4637/4720|                                                                        |

SD, standard deviation; ISS, injury severity score; GCS, Glasgow Coma Scale

**Interventions**

Nine triage tools were examined, based on Newgard et al in which triage tools were derived by statistically analysing a retrospective cohort study conducted at 6 sites in the Western US between January 2006 and December 2008.\[13\] This study was selected as it fit nine triage tools to one dataset, so represented feasible trade-offs between sensitivity and specificity for any new rule. These analyses produced nine triage tools for which, the reported sensitivities and specificities for each tool were:

- Sensitivity 99.8%, Specificity 2.5%
- Sensitivity 94.8%, Specificity 18.7%
- Sensitivity 90.4%, Specificity 58.4%
- Sensitivity 87.5%, Specificity 62.8%
- Sensitivity 74.6%, Specificity 65.7%
- Sensitivity 69.8%, Specificity 70.1%
- Sensitivity 64.2%, Specificity 76.1%
- Sensitivity 57.0%, Specificity 80.0%
- Sensitivity 99.8%, Specificity 88.6%

We assumed that the sensitivity and specificity values for each triage tool represented the final triage decision, combining the diagnostic accuracy of the triage tool and the application of judgement by the on-scene paramedics. A recent analysis of a Dutch triage tool in an English data set produced a receiver-operator curve that would result in similar triage tool sensitivity and specificity as observed by Newgard et al\[14\]

**Perspective**

In line with guidance from the English and Welsh decision maker, the National Institute for Health and Care Excellence (NICE): we undertook a cost-utility analysis; our analyses had a lifetime horizon; an NHS and personal social services perspective was taken; and, future costs and QALYs were discounted at 3.5%.\[15\]

**Outcome measures**

The primary outcome measure of the model was the incremental cost-effectiveness ratio (ICER). Key secondary outcomes of the model included: life expectancy; discounted costs; discounted QALYs; the number of patients who died prior to discharge; the number of patients who died between discharge and...
The ICERs between the strategies were calculated as difference in cost / difference in QALYs. As we have a decision problem with multiple strategies, a full incremental analysis was undertaken in line with the NICE methods guide.[15] In this approach strategies are ordered by their effectiveness (measured in QALYs). Any tools that are dominated (they produce less QALYs at a higher cost than another tool) or extendedly dominated (a combination of two other tools can produce the same QALYs at a lower cost) were removed from consideration. ICERs were then calculated comparing each remaining tool, except the least effective tool, to the next least effective remaining tool.

The maximum acceptable ICER (MAICER), is the amount of money that a decision-maker is willing to pay to gain 1 additional QALY. NICE’s MAICER is usually considered to be £20,000 per QALY, but may increase to £30,000, as detailed in the NICE methods guide.[15] In a full incremental analysis, the most effective tool with an ICER below the decision maker’s MAICER is the cost-effective tool.

**Model Structure and Logic**

A diagram of the model is presented in Figure 1. Patients enter the model and the sensitivity and specificity of the triage tool determines whether they go to the MTC or local hospital. For patients who go to a local hospital, there is a probability that they will undergo secondary transfer to the MTC. For patients who the triage tool suggests that they go directly to the MTC, there is a chance that they will initially go to a local hospital for urgent care after which they will undergo a secondary transfer to the MTC. Any patient who goes to the MTC will gain the full benefit from MTC care, but all patients who undergo a secondary transfer will incur costs for an additional ambulance callout. Post-admission, each patient’s probability of survival within 30 days is estimated. Patients with an ISS of 16 or more and who did not go to an MTC, have a relative risk of death applied to their 30 day survival probability to reflect the poorer outcomes we expect for these patients. Patients who survive up until 30 days post-injury, have their probability of survival up to one year post-injury estimated. Again, a relative risk of death was applied to increase the probability of death for patients with an ISS of 16 or more who did not receive MTC care. Patients who survive up to one year post-injury, enter a long-term discrete event simulation in which their life expectancy is estimated using general population mortality data, increased by a hazard ratio dependent on their ISS, to estimate their expected remaining life expectancy. This model was developed in R v4.0.2.[16]

**Probability of events and effectiveness of MTCs**

We used the same evidence as the previously published Newgard et al economic model for the effectiveness of MTCs on patient outcomes. These studies are analyses of large cohort studies in a North American setting.[2–4] The data on the probability of death was updated to include UK data, where this was known to exist. The 2006 TARN survival prediction model was selected for use in our base case economic model, as our patient cohort did not have information on comorbidities which is required in the 2015 TARN survival equation.[10, 11]

Table 2: A summary of the parameters used in the model.
### Clinical parameters

| Parameter                                                                 | Value  | Source                          |
|---------------------------------------------------------------------------|--------|---------------------------------|
| Probability of patients having a transfer from a local hospital to an MTC if: |        |                                 |
| They were a true positive (ISS ≥ 16 & tool positive)                        | 26.6%  | Newgard et al 2016[32]          |
| They were a false negative (ISS ≥ 16 & tool negative)                       | 32.5%  |                                 |
| They were a true negative (ISS < 16 & tool negative)                        | 4.3%   |                                 |
| They were a false positive (ISS < 16 & tool positive)                       | 7.4%   |                                 |
| Probability of death within 30 days                                         |        |                                 |
| Relative risk of death within 30 days of hospitalisation for patients with an ISS ≥ 16 who were treated at a local hospital | 1.25   | Newgard et al 2013[3]           |
| Relative risk of death within 30 days of hospitalisation for patients with an ISS < 16 who were treated at a local hospital | 1      | Assumption                      |
| Probability of death between 30 days post-injury and 1-year post-injury for patients with an ISS ≥ 16 | 3.6% | Mackenzie et al. 2006[2]          |
| Relative risk of death between 30 days and 1 year post-hospitalisation for patients with an ISS ≥ 16 who were treated at an local hospital | 1.64  |                                 |
| Probability of death between 30 days post-injury and 1 year post-injury for patients with an ISS < 16 | 1.7% | Davidson et al 2011[33]          |
| Probability of death after 1 year                                           |        |                                 |
| Hazard Ratio for the risk of death if someone has a suspected major trauma case with: |        |                                 |
| An ISS of less than 16                                                     | 1.38   | Newgard et al 2016[9]           |
| An ISS of greater than or equal to 16                                       | 5.19   | Cameron et al. 2005[4]          |

### Utility parameters

| Parameter                                                                 | Value   | Source                          |
|---------------------------------------------------------------------------|---------|---------------------------------|
| Utility for patients with:                                                |         |                                 |
| An ISS of 16 or more                                                      | 0.65    | Ahmed et al[17]                 |
| An ISS of 15 or less                                                      | 0.65    |                                 |
| General population utility                                                |         |                                 |
| Constant                                                                  | 0.9508566 | Ara and Brazier[35]             |
| Age                                                                       | -0.0002587 |                                 |
| Age squared                                                               | -0.0000332 |                                 |
| Male (1 = male, 0 = otherwise)                                            | 0.0212126 |                                 |
| Calculations                                                              |         |                                 |
| Age and gender matched general population utility for the Ahmed et al population | 0.824  | Calculated. Mean age was 61 years and 59.1% of the analysis population was male in Ahmed et al[17] |
| Utility multipliers, relative to the utility in the general population, for patients with: |         |                                 |
| An ISS of 16 or more                                                      | 0.789   | Calculated                      |
| An ISS between 15 and 9                                                   | 0.789   | Calculated                      |
| An ISS of under 9                                                         | 1       | We assumed that these patients would have a utility equal to that of the general population |

### Cost Parameters

| Parameter                                                                 | Value   | Source                          |
|---------------------------------------------------------------------------|---------|---------------------------------|
| Admission costs – base case                                               |         |                                 |
Transfers between local hospitals and MTCs £252 Assumed to be one additional ambulance call out. NHS improvement[23] Currency Code ASS02.

MTC admission, if ISS is 16 or over £2,819 NHS improvement[22]

MTC admission, if ISS is less than 16 and over 8 £1,466

Treatment of a patient with blunt trauma and an ISS in the range of:

| ISS   | Cost   | Source                        |
|-------|--------|-------------------------------|
| ≤9    | £6,198 | Christensen et al[20]         |
| 9<ISS≤16 | £8,989 |                               |
| 16<ISS≤25 | £14,205 |                               |
| ISS > 25 | £21,173 |                               |

Treatment of a patient with penetrating trauma and an ISS in the range of:

| ISS   | Cost   | Source                        |
|-------|--------|-------------------------------|
| ≤9    | £6,501 | Christensen et al[21]         |
| 9<ISS≤15 | £6,035 |                               |
| 15<ISS≤24 | £9,453 |                               |
| 24<ISS≤34 | £12,347 |                               |
| ISS > 34 | £16,438 |                               |

Post discharge costs

| Description                                      | Cost   | Source                        |
|------------------------------------------------|--------|-------------------------------|
| Cost between discharge and 6 months post treatment | £1,766 | John Nichol, Personal communication |

Relative increase in lifetime treatment costs for patients with an ISS ≥ 16 compared to the general population

| Comparison | Relative Increase | Source                                    |
|------------|-------------------|-------------------------------------------|
| ISS ≥ 16  | 1.45              | Cameron et al 2006[25] Delgado et al 2013[24] |

Relative increase in lifetime treatment costs for patients with an ISS < 16 compared to the general population

| Comparison | Relative Increase | Source                                    |
|------------|-------------------|-------------------------------------------|
| ISS < 16  | 1.25              | Cameron et al 2006[25] Delgado et al 2013[24] |

Yearly costs of NHS treatment

| Category              | Cost   | Source                        |
|-----------------------|--------|-------------------------------|
| Age and gender dependent | £1,766 | Asaria 2017[26]               |

NB – distributions and the standard errors around each parameter are provided in the appendix.

Utilities

The utility parameters used in the model are provided in Table 2. Our utilities are from Ahmed et al, which is a survey in which 154 patients, whose ISS was 9 or more, completed the EQ-5D-5L questionnaire at an English MTC one year post-injury.[17] There was no evidence in this study that utility varied by ISS score. For patients with an ISS of 9 or more we applied these utilities multiplicatively to age-gender matched utilities for the UK general population.[18] For patients with an ISS of less than 9 we assumed that their injury did not have long term effects on their utility.

Costs

The costs in the model reflect English practice and are provided in Table 2. All costs are in 2017/18 prices. Costs from previous years were inflated to 2017/18 prices using the HCHS Pay and Prices inflation index.[19] Other costs incurred within the first 6 months post-injury were obtained from UK based studies and sources.[20–23][John Nicholl, personal communication] After 6 months we adopt the data reported in Delgado et al, which was a cost-effectiveness analysis of helicopter versus ground transport in the US.[24] These parameters, which is that based on data from one Canadian study, are an increase in costs for patients with a history of trauma compared to the general population.[25] We used English health care costs incurred by the general population, according to their age and gender, and the data from Delgado et al to calculate the increased long term health care costs incurred by each patient in our model.[24, 26]

Scenario analyses

A base case deterministic analysis was performed, where all parameters are set to mean values. In order to account for the uncertainty in model inputs a probabilistic sensitivity analysis (PSA) was conducted using Monte Carlo simulation to randomly sample from a distribution assigned to each model parameter (see Appendix). Multiple model runs were performed, each with independent random draws from every parameter's distribution. ICERs were calculated from the mean expected costs and effects over all model runs. We assessed the stability of our model results with respect to the number of patients (assessed visually) and number of PSA runs (assessed using the Hatswell et al method).[27] We found that 25,000 simulated patients and 2,000 PSA runs produced stable results (see Appendix).

We conducted three scenario analyses to explore the robustness of model assumptions.
In the first scenario analysis we used the 2015 TARN survival equation and assumed that the simulated patients in our model were in the same risk category as people with missing Charlson Comorbidity Index (CCI).[11]

In the second scenario analysis, we explored the benefit of MTC care to patients with an ISS between 9 and 15 inclusive, as these patients incur costs for going to an MTC in England implying there may be a belief by payers that these patients would benefit from MTC care.

In the final set of scenario analyses we varied the cost of MTC care, as the cost of MTC care in England is reviewed regularly.

**Results**

**Base Case analysis**

The results of the deterministic base case analysis is given in Table 3. All ICERs are in excess of £30,000 per QALY gained, consequently they are above the upper limit of the ICER that NICE would consider acceptable meaning that the cost-effective strategy is the least sensitive triage tool.[15] The PSA results are given in Table 3. The PSA results, in terms of the ICERs and the tools which are dominated or extendedly dominated, are very different to the deterministic results. Consequently all conclusions and scenario analyses are based on the PSA results, as the difference between the deterministic and PSA results for the base case indicates that conducting deterministic analysis introduces bias into the estimated ICER (non-linearity).[27]

In the PSA results, a low sensitivity and high specificity tool results in the least number of cases going to an MTC, the lowest cost and the worst outcomes (probability of death, life expectancy and QALYs). Conversely a highly sensitive and low specificity tool results in the most cases going to an MTC, the highest cost, and the best outcomes. Three strategies have ICERs above £20,000 per QALY gained, but below £30,000 per QALY gained (57% sensitivity, 64.2% sensitivity, 87.5% sensitivity). The two remaining strategies, that were not dominated or extendedly dominated, had ICERs that were above the usual upper limit of NICE's MAICER of £30,000 per QALY gained.

The model results indicate that out of a population of 100,000 patients to whom a major trauma triage tool was applied, 18,448 out of the 100,000 assessed patients would go to an MTC using the most specific tool whereas 97,860 of the 100,000 assessed patients would go to the MTC using the most sensitive tool. Even when using a very specific triage tool, the majority patients with an ISS ≥ 16 would go to an MTC due to transfers from the local hospitals.
| Triage Tool | Number of cases sent to the MTC per 100,000 patients | Number of cases sent to the MTC per 8,916 patients (ISS ≥ 16) | Number of cases sent to the MTC per 91,084 patients (ISS < 16) | Proportion of patients who died before discharge | Proportion of patients who died between discharge and 1-year post-injury | Mean years lived | Mean discounted QALYs | Mean discounted Costs | ICER |
|-------------|----------------------------------------------------|----------------------------------------------------------------|---------------------------------------------------------------|-----------------------------------------------|-------------------------------------------------------------|----------------|-----------------------|---------------------|------|
| Deterministic | 28.4% Sens, 88.6% Spec | 18,912 | 4,600 | 14,312 | 4.17% | 1.80% | 32.07 | 13.620 | £32,574 | - |
| | 57.0% Sens, 80.0% Spec | 28,120 | 6,220 | 21,900 | 4.14% | 1.78% | 32.08 | 13.624 | £32,698 | ED |
| | 64.2% Sens, 76.1% Spec | 31,892 | 6,724 | 25,168 | 4.12% | 1.78% | 32.08 | 13.625 | £32,743 | ED |
| | 69.8% Sens, 70.1% Spec | 37,536 | 7,092 | 30,444 | 4.11% | 1.77% | 32.08 | 13.626 | £32,774 | ED |
| | 74.6% Sens, 65.7% Spec | 41,672 | 7,392 | 34,280 | 4.10% | 1.78% | 32.08 | 13.626 | £32,794 | ED |
| | 87.5% Sens, 62.8% Spec | 44,976 | 8,156 | 36,820 | 4.09% | 1.76% | 32.09 | 13.629 | £32,825 | £33,026 |
| | 90.4% Sens, 58.4% Spec | 49,100 | 8,364 | 40,736 | 4.08% | 1.75% | 32.09 | 13.630 | £32,889 | £39,584 |
| | 94.8% Sens, 18.7% Spec | 83,116 | 8,612 | 74,504 | 4.08% | 1.75% | 32.09 | 13.630 | £32,979 | ED |
| | 99.8% Sens, 2.5% Spec | 97,860 | 8,912 | 88,948 | 4.06% | 1.74% | 32.10 | 13.633 | £33,064 | £54,515 |
| Probabilistic (all values are mean values) | 28.4% Sens, 88.6% Spec | 18,448 | 4,607 | 13,841 | 4.78% | 1.78% | 32.05 | 13.580 | £33,024 | - |
| | 57.0% Sens, 80.0% Spec | 27,670 | 6,331 | 21,339 | 4.72% | 1.76% | 32.07 | 13.586 | £33,181 | £25,039 |
| | 64.2% Sens, 76.1% Spec | 31,505 | 6,763 | 24,741 | 4.70% | 1.75% | 32.07 | 13.588 | £33,223 | £27,311 |
| | 69.8% Sens, 70.1% Spec | 37,069 | 7,100 | 29,969 | 4.69% | 1.75% | 32.07 | 13.589 | £33,262 | ED |
| | 74.6% Sens, 65.7% Spec | 41,192 | 7,388 | 33,804 | 4.68% | 1.74% | 32.08 | 13.590 | £33,294 | ED |
| | 87.5% Sens, 62.8% Spec | 44,499 | 8,165 | 36,334 | 4.65% | 1.73% | 32.08 | 13.593 | £33,363 | £27,624 |
Triage Tool | Number of cases sent to the MTC per 100,000 patients | Number of cases sent to the MTC per 8,916 patients (ISS ≥ 16) | Number of cases sent to the MTC per 91,084 patients (ISS < 16) | Proportion of patients who died before discharge | Proportion of patients who die between discharge and 1-year post-injury | Mean years lived | Mean discounted QALYs | Mean discounted Costs | ICER |
---|---|---|---|---|---|---|---|---|---|---|
90.4% Sens, 58.4% Spec | 48,516 | 8,339 | 40,177 | 4.65% | 1.73% | 32.08 | 13.594 | £33,386 | £35,791 |
94.8% Sens, 18.7% Spec | 83,383 | 8,603 | 74,779 | 4.64% | 1.72% | 32.09 | 13.594 | £33,486 | ED |
99.8% Sens, 2.5% Spec | 97,810 | 8,904 | 88,906 | 4.62% | 1.72% | 32.09 | 13.596 | £33,542 | £77,477 |

MTC, major trauma centre; ISS, injury severity score; QALYS, quality adjusted life years; ICER, incremental cost-effectiveness ratio; Sens, sensitivity; Spec, specificity; ED, extendedly dominated

**Scenario analyses**

Table 4 summarises the results of the scenario analyses. When the TARN 2015 survival equation is used and all patients in our simulation are treated as having a missing CCI, the results are remarkably similar to the base case analysis as the strategies which are cost-effective at £20,000 and £30,000 per QALY gained are the same.[11] In the scenario analyses in which patients with an ISS between 9 and 15 inclusive receive a benefit from MTC care, the conclusions of the base case are changed. If the benefit that these patients receive is 25% or 50% of the benefit accrued from MTC care by patients with an ISS of 16 or more, then the most cost-effective tool at an MAICER of £30,000 per QALY gained is the most sensitive triage tool. Although when these patients receive 50% of the benefit of MTC care, the ICER for the most sensitive strategy is only £20,306 per QALY gained (see Appendix) indicating that the NICE’s ICER would only have to be a very small amount over the lower end of their usual range of MAICERS to consider the most sensitive rule to be cost-effective in this scenario. In the scenario where these patients receive 75% of the benefit of MTC care that is accrued by patients with an ISS over 16, then the most sensitive triage tool would be cost-effective at MAICERS of both £20,000 and £30,000 per QALY gained.

| Scenario | Cost-effective tool at £20,000 per QALY gained | Cost-effective tool at £30,000 per QALY gained |
|---|---|---|
| Base Case | 28.4% Sens, 88.6% Spec | 87.5% Sens, 62.8% Spec |
| **Scenario analyses** | | |
| TARN 2015 survival equation with every patient’s CCI being missing | 28.4% Sens, 88.6% Spec | 87.5% Sens, 62.8% Spec |
| **MTC benefit for people with and ISS in the range 16 > ISS ≥ 9** | | |
| MTCs have 25% benefit | 28.4% Sens, 88.6% Spec | 99.8% Sens, 2.5% Spec |
| RR of death prior to discharge = 1.07 | | |
| RR of death discharge and one year = 1.16 | | |
| MTCs have 50% benefit | 28.4% Sens, 88.6% Spec | 99.8% Sens, 2.5% Spec |
| RR of death prior to discharge = 1.13 | | |
| RR of death discharge to one year = 1.32 | | |
| MTCs have 75% benefit | 99.8% Sens, 2.5% Spec | 99.8% Sens, 2.5% Spec |
| RR of death prior to discharge = 1.19 | | |
| RR of death discharge to one year = 1.48 | | |
| **Full results are given in the Appendix** | | |

QALY, quality adjusted life year; Sens, sensitivity; Spec, specificity; TARN, Trauma Audit and Research Network; CCI, Charlson comorbidty index; MTCs, major trauma centres; RR, relative risk

Table 5 shows the tool that is cost-effective when the cost of MTC care in England is changed. This is assessed at MAICERS of £20,000 and £30,000 per QALY gained. At an MAICER of £20,000 the optimal tool is highly sensitive to the level of best practice tariffs for MTCs in the UK. If the tariffs are set to their 2017/18 levels, then the optimal tool is a highly specific triage tool. If the tariffs were set to £0, then the optimal tool would be a tool with a sensitivity of 88% and a specificity of 63%. These results are similar at MAICERS of £30,000 per QALY gained, with either the tool with a sensitivity of 88% or a sensitivity of 90% being cost-effective.
Table 5
Cost-effective triage tool in the threshold analyses on the cost of MTC care in England

| MAICER = £20,000 per QALY gained | Cost of MTC care for patients with: | £1541 (2020/21 tariff levels) | £1,466 (100%) | £1099.50 (75%) | £733 (50%) | £366.50(25%) |
|----------------------------------|------------------------------------|-------------------------------|----------------|----------------|-----------|--------------|
| ISS ≥ 16 (rows)                  |                                    | £1541                         | £1,466 (100%)  | £1099.50 (75%) | £733 (50%)| £366.50(25%) |
| 16 > ISS ≥ 9 (columns)           |                                    | £1541                         | £1,466 (100%)  | £1099.50 (75%) | £733 (50%)| £366.50(25%) |
| £2961 (2020/21 tariff levels)    | 28.4% Sens 88.6% Spec              | 28.4% Sens 88.6% Spec         | 28.4% Sens 88.6% Spec | 28.4% Sens 88.6% Spec | 57.0% Sens 80.0% Spec |
| £2,819 (100%)                    | 28.4% Sens 88.6% Spec              | 28.4% Sens 88.6% Spec         | 28.4% Sens 88.6% Spec | 28.4% Sens 88.6% Spec | 57.0% Sens 80.0% Spec |
| £2114.25 (75%)                   | 28.4% Sens 88.6% Spec              | 28.4% Sens 88.6% Spec         | 28.4% Sens 88.6% Spec | 28.4% Sens 88.6% Spec | 57.0% Sens 80.0% Spec |
| £1409.50 (50%)                   | 28.4% Sens 88.6% Spec              | 28.4% Sens 88.6% Spec         | 28.4% Sens 88.6% Spec | 28.4% Sens 88.6% Spec | 57.0% Sens 80.0% Spec |
| £704.75 (25%)                    | 28.4% Sens 88.6% Spec              | 28.4% Sens 88.6% Spec         | 28.4% Sens 88.6% Spec | 28.4% Sens 88.6% Spec | 87.5% Sens 62.8% Spec |

| MAICER = £30,000 per QALY gained | Cost of MTC care for patients with: | £1541 (2020/21 tariff levels) | £1,466 (100%) | £1099.50 (75%) | £733 (50%) | £366.50(25%) |
|----------------------------------|------------------------------------|-------------------------------|----------------|----------------|-----------|--------------|
| ISS ≥ 16 (rows)                  |                                    | £1541                         | £1,466 (100%)  | £1099.50 (75%) | £733 (50%)| £366.50(25%) |
| 16 > ISS ≥ 9 (columns)           |                                    | £1541                         | £1,466 (100%)  | £1099.50 (75%) | £733 (50%)| £366.50(25%) |
| £1541 (2020/21 tariff levels)    | 87.5% Sens 62.8% Spec              | 87.5% Sens 62.8% Spec         | 87.5% Sens 62.8% Spec | 90.4% Sens 58.4% Spec | 87.5% Sens 62.8% Spec |
| £2,819 (100%)                    | 87.5% Sens 62.8% Spec              | 87.5% Sens 62.8% Spec         | 87.5% Sens 62.8% Spec | 87.5% Sens 62.8% Spec | 87.5% Sens 62.8% Spec |
| £2114.25 (75%)                   | 87.5% Sens 62.8% Spec              | 87.5% Sens 62.8% Spec         | 87.5% Sens 62.8% Spec | 90.4% Sens 58.4% Spec | 90.4% Sens 58.4% Spec |
| £1409.50 (50%)                   | 90.4% Sens 58.4% Spec              | 90.4% Sens 58.4% Spec         | 90.4% Sens 58.4% Spec | 90.4% Sens 58.4% Spec | 90.4% Sens 58.4% Spec |
| £704.75 (25%)                    | 90.4% Sens 58.4% Spec              | 90.4% Sens 58.4% Spec         | 90.4% Sens 58.4% Spec | 90.4% Sens 58.4% Spec | 99.8% Sens 2.5% Spec |

MAICER, maximum acceptable incremental cost-effectiveness ratio; ISS, injury severity score; Sens, sensitivity; Spec, specificity

Full results as per the base case analysis are available in the Appendix

Discussion

Summary of findings

The cost-effective triage tool for patients with suspected major trauma is highly uncertain, as three potential tools have emerged with ICERs within the range of £20,000 to £30,000 per QALY gained. If the MAICER in the UK for this problem is £20,000 per QALY gained, then the cost-effective triage tool will be a highly specific tool. However, if the MAICER in the UK for this problem is £30,000 per QALY gained then the cost-effective triage tool will be a moderately sensitive tool with a sensitivity in the region of 85–90%. The sensitivity of these tools are slightly lower than the American College of Surgeons Committee on Trauma's (ACSCOT) recommended sensitivity for any new tool of 95%.[28] The key uncertainties in our ICERs relate to the benefit that MTCs offer to patients with an ISS of between 9 and 15. If this subgroup of patients gains a benefit from MTC care, then the cost-effective tool may be a highly sensitive tool. Furthermore, the results are sensitive to the current cost of MTC care in England, which is determined by best practice tariffs payments made to hospitals.

When deciding upon the exact MAICER used for a decision problem in England, NICE committees consider: how certain the ICERs are; whether health related quality of life has been adequately captured in utilities; whether they believe the technology is innovative; and, whether the technology helps the NHS meet its non-health objectives. As the MAICERs increase from £20,000 to £30,000 per QALY gained, the committee will make explicit references to these criteria in their judgement as to whether a new technology is cost-effective. Therefore, if the moderately sensitive tool was to be judged cost-effective in our base case analysis, then the tool would have to be judged as meeting one or more of these additional criteria by a NICE guidelines committee on major trauma.

Comparison to previous literature

Despite large-scale investment in major trauma networks, the cost-effectiveness of major trauma triage is not well studied, with only one previously published economic model available by Newgard et al.[9] They found in a US setting, implementing a high sensitivity tool (as recommended by ASCOT) was unlikely to
be cost-effective. This conclusion is very similar to our findings and shows that developing high sensitivity tools for major trauma are likely to not be a cost-effective use of resources in either the UK or the US based on our current understanding of major trauma systems.

**Strength and Limitations**

This model is the first model of major trauma set in the UK that we are aware of, follows best practice recommendations for health economic evaluations, and brings together the best available evidence to inform decision making on major trauma centres in the England. However, there are a number of limitations in the underlying evidence base that must be taken into account when considering the results and when designing future research projects designed to make well-informed decisions regarding major trauma care in an English or UK wide context.

Firstly, all the clinical evidence underpinning the model related to a definition of major trauma based solely on patient's ISS. However, ISS may not be the gold standard definition of major trauma with a new criterion for patients who benefit from major trauma existing.[7, 29, 30] Secondly, a Dutch cohort was used to simulate patients in our model. This provided a high quality data set which should be representative of patients in the developed world, however complete generalisability to the UK, or other settings cannot be guaranteed.[12] Thirdly, whilst most of the data in this model is from the UK setting, further research on the effectiveness of MTCs, the probability of receiving an secondary transfer to an MTC, the effect of having major trauma on patient's long-term outcomes in a UK setting, and the total number of patients with an ISS ≥ 16 not transported to an MTC would be desirable. Fourthly, it is thought that patients who go directly to MTCs have better outcomes than patients who receive secondary transfers to the MTC, however quantitative evidence on this effect is lacking meaning that this cannot be accurately quantified in our analyses. Fourthly, the data on the health care costs incurred by major trauma patients in the UK is old, as it uses TARN data from 2000 to 2005. Therefore, an update of this evidence would be a useful addition to this model. There is a partial update to this evidence, which uses TARN data from 2009 to 2011.[31] However, the population of this study was limited to patients with major trauma who also had severe bleeding. Finally, to conduct a simulated population it was necessary to exclude patients with missing data from the Dutch Cohort.

**Future Research**

As highlighted in the strengths and limitations there are several key areas of research that would improve decision making in the area of major trauma triage these include:

1) Estimating the effectiveness of MTC care for patients who meet the Lerner et al. criteria of major trauma centre need, rather than ISS.[7] Without this evidence we cannot reliably estimate the cost-effectiveness of triage tools designed around these criteria.

2) The evidence on the cost of major trauma cases (especially in the long term) in the UK NHS should be updated.

3) Further research should be conducted into whether patients with an ISS of between 9 and 15 receive any benefit from MTC care.

4) Quantifying the benefit of MTCs for patients sent directly to the MTCs and the patients who receive a secondary transfers should estimated separately.

**Implications for practice**

This work indicates that based on the current major trauma system in England and the best currently available evidence, if a cost-effective rule is to be selected then we have to accept a non-negligible proportion of severely injured patients (at least 10%) will not initially be identified as needing care at a major trauma centre. Based on current evidence we would expect around 30% of these patients to be transferred to an MTC, but that still leaves 7% of all major trauma cases not receiving the best available care.

**Conclusion**

In conclusion, cost-effective prehospital trauma triage involves clinically suboptimal sensitivity unless it can be proved that patients with an ISS between 9 and 15 receive a significant benefit from MTC care. Cost-effective trauma triage tools result in a proportion of severely injured patients (at least 10%) being initially transported to local hospitals. Implementing high sensitivity trauma triage tools in England requires development of more accurate decision rules; research to establish if patients with an ISS between 9 and 15 benefit from MTCs; changes in the MTC funding system in England; or, inefficient use of health care resources to manage patients with less serious injuries at MTCs.

**Abbreviations**

List of abbreviations
| Abbreviation | Meaning |
|--------------|---------|
| MTCs         | Major trauma centres |
| ISS          | Injury Severity Score |
| QALYs        | Quality adjusted life years |
| TARN         | Trauma audit research network |
| GCS          | Glasgow coma Scale |
| NICE         | National Institute for Health and Care Excellence |
| ICER         | Incremental cost-effectiveness ratio |
| MAICER       | Maximum acceptable incremental cost-effectiveness ratio |
| PSA          | Probabilistic sensitivity analysis |
| CCI          | Charlson Comorbidity Index |

**Declarations**

**Ethics approval, guidelines and consent to participate**

The Major Trauma Triage Study, of which this analysis of part, has ethical approval from Bradford Leeds Research Ethics Committee (REC 28th June 2019, Reference number 19/YH/0197). All substantial protocol amendments were approved by Bradford Leeds REC and the Health Research Authority (HRA) before implementation.

The data collected by University Medical Center Utrecht was judged by the Medical Ethical Committee of University Medical Center Utrecht, Utrecht, the Netherlands, as not subject to the Medical Research Involving Human Subjects Act and therefore exempt from the need for informed consent.

The study was performed in accordance with the ethical standards of the Declaration of Helsinki (1964) and its subsequent amendments.

**Consent for publication**

Not applicable, the only individual patient data used in these analyses was exempt for the need for informed consent.

**Availability of data and materials**

The data from van Rein *et al.*[8] was accessed by request from MH.

The model code, PSA parameters and patient characteristics are available open access under a MIT licence. These are given at: [https://doi.org/10.15131/shef.data.13379036.v2](https://doi.org/10.15131/shef.data.13379036.v2)

**Competing interests**

No authors report any competing interests.

**Funding**

This study/project is funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme (grant number 17/16/04). The NIHR had no control over the conduct of the study. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

**Author contributions**

DP had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis

*Conception and design:* DP, GF, SG

*Acquisition, analysis, or interpretation of data:* DP, GF, SG, EAJR, JFW and MH

*Drafting of the manuscript:* DP, GF, SG

*Critical revision of the manuscript for important intellectual content:* EAJR, JFW, MH

*Model development and Economic analysis:* DP

**Acknowledgements**

None
References

1. World Health Organization. Injuries and Violence The Facts 2014. 2014; 20. https://apps.who.int/iris/bitstream/handle/10665/149798/9789241508018_eng.pdf?sequence=1. Accessed 18 Nov 2020.
2. MacKenzie EJ, Rivara FP, Jurkovich GJ, Nathens AB, Frey KP, Egleston BL, et al. A National Evaluation of the Effect of Trauma-Center Care on Mortality. N Engl J Med. 2006;354:366–78.
3. Newgard CD, Staudenmayer K, Hsia RY, Mann NC, Bulger EM, Holmes JF, et al. The cost of overtriage: More than one-third of low-risk injured patients were taken to major trauma centers. Health Aff. 2013.
4. Cameron CM, Purdie DM, Kileweer E V., McClure RJ. Long-term mortality following trauma: 10 Year follow-up in a population-based sample of injured adults. J Trauma - Inj Infect Crit Care. 2005.
5. Cudnik MT, Newgard CD, Sayre MR, Steinberg SM. Level I versus level II trauma centers: An outcomes-based assessment. J Trauma - Inj Infect Crit Care. 2009.
6. Polites SF, Leonard JM, Glasgow AE, Zielinski MD, Jenkins DH, Habermann EB. Undertriage after severe injury among United States trauma centers and the impact on mortality. Am J Surg. 2018.
7. Lerner EB, Willenbring BD, Pirrallio RG, Brasel KJ, Cady CE, Colella MR, et al. A consensus-based criterion standard for trauma center need. In: Journal of Trauma and Acute Care Surgery. 2014.
8. van Rein EAJ, van der Sluijs R, Houwert RM, Gunning AC, Lichtveld RA, Leenen LPH, et al. Effectiveness of prehospital trauma triage systems in selecting severely injured patients: Is comparative analysis possible? American Journal of Emergency Medicine. 2018.
9. Newgard CD, Yang Z, Nishijima D, McConnell KJ, Trent SA, Holmes JF, et al. Cost-effectiveness of field trauma triage among injured adults served by emergency medical services. J Am Coll Surg. 2016.
10. Bouamra O, Wrotchford A, Hollis V, Vail A, Woodford M, Lecky F. Outcome prediction in trauma. Injury. 2006.
11. Bouamra O, Jacques R, Edwards A, Yates DW, Lawrence T, Jenks T, et al. Prediction modelling for trauma using comorbidity and “true” 30-day outcome. Emerg Med J. 2015.
12. Van Rein EAJ, Van der Sluijs R, Voskens FJ, Lansink KWW, Houwert RM, Lichtveld RA, et al. Development and Validation of a Prediction Model for Prehospital Triage of Trauma Patients. JAMA Surg. 2019.
13. Newgard CD, Hsia RY, Mann NC, Schmidt S, Sahni R, Bulger EM, et al. The trade-offs in field trauma triage: A multiregion assessment of accuracy metrics and volume shifts associated with different triage strategies. J Trauma Acute Care Surg. 2013.
14. Shanahan T, Fuller GW, Sheldon T, Turton E, Quilty FMA, Marincoqitz C. External validation of the Dutch prediction model for prehospital triage of trauma patients in South West region of England, United Kingdom. Forthcommi.
15. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal. Online Source. 2013;Available Last Accessed: 17th March 2016;1–93. doi:10.2165/00019053-200826090-00002.
16. R Core Team (2019). R: A language and environment for statistical computing. Accessed 1st April 2019. 2019.
17. W. A, R. A, Ahmed W, Alwe R, Wade D. One-year functional outcomes following major trauma: experience of a UK level 1 major trauma centre. Clin Rehabil. 2017;31:1646–52. doi:https://dx.doi.org/10.1177/0269215517712044.
18. Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Heal. 2010;13:509–18. doi:10.1111/j.1524-7333.2010.00700.x.
19. Curtis L, Burns A. Unit Costs of Health and Social Care 2018. Online Source. 2019;Available Last Accessed 19th July 2019.
20. Christensen MC, Ridley S, Lecky FE, Munro V, Morris S. Outcomes and costs of blunt trauma in England and Wales. Crit Care. 2008.
21. Christensen MC, Nielsen TG, Ridley S, Lecky FE, Morris S. Outcomes and costs of penetrating trauma injury in England and Wales. Injury. 2008.
22. NHS Improvement. 2017/18 and 2018/19 National Tariff Payment System. Online Source Available from https://improvement.nhs.uk/resources/reference-costs/. 2019; Last Accessed: 19th July 2019.
23. NHS Improvement. 2017/18 reference cost data. Online Source Available from https://improvement.nhs.uk/resources/reference-costs/. 2019; Last Accessed 19th July 2019.
24. Delgado MK, Staudenmayer KL, Wang NE, Spain DA, Weir S, Owens DK, et al. Cost-effectiveness of helicopter versus ground emergency medical services for trauma scene transport in the United States. Ann Emerg Med. 2013.
25. Cameron CM, Purdie DM, Kileweer E V., McClure RJ. Ten-year health service use outcomes in a population-based cohort of 21 000 injured adults: The Manitoba Injury Outcome Study. Bull World Health Organ. 2006.
26. Asaria M. Health care costs in the English NHs: reference tables for average annual NHS spend by age, sex and deprivation group. Unit Costs Heal Soc Care. 2017;16–21.
27. Hatswell AJ, Bullement A, Briggs A, Paulden M, Stevenson MD. Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models. Pharmacoeconomics. 2018.
28. Criteria R. Resources for optimal care of the injured patient 2006. Chicago Am ... 2006.
29. Newgard CD, Fu R, Zive D, Rea T, Malveaux S, Daya M, et al. Prospective Validation of the National Field Triage Guidelines for Identifying Seriously Injured Persons. J Am Coll Surg. 2016.
van der Sluijs R, Lokerman RD, Waalwijk JF, de Jongh MAC, Edwards MJR, den Hartog D, et al. Accuracy of pre-hospital trauma triage and field triage decision rules in children (P2-T2 study): an observational study. Lancet Child Adolesc Heal. 2020.

Campbell HE, Stokes EA, Bargo DN, Curry N, Lecky FE, Edwards A, et al. Quantifying the healthcare costs of treating severely bleeding major trauma patients: A national study for England. Crit Care. 2015.

Newgard CD, Yang Z, Nishijima D, McConnell KJ, Trent SA, Holmes JF, et al. Cost-effectiveness of field trauma triage among injured adults served by emergency medical services. J Am Coll Surg. 2016;222:1125–37. doi:http://dx.doi.org/10.1016/j.jamcollsurg.2016.02.014.

Davidson GH, Hamlat CA, Rivara FP, Koepsell TD, Jurkovich GJ, Arbabi S. Long-term survival of adult trauma patients. JAMA - J Am Med Assoc. 2011.

Office for National Statistics. National life tables: UK 2015-2017. Online Source Available from https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/lifeexpectancies/datasets/nationallifetablesunitedkingdomreference

Ara R, Brazier JE. Populating an economic model with health state utility values: Moving toward better practice. Value Heal. 2010.

**Figures**

![Model Structure](image)

**Figure 1**

The model structure

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- BMCemergencymedicinepaperAppendixSubmittedApril2021.docx